David Deems joined Xceed Molecular from Predicant Biosciences, an early stage proteomics company working to identify protein patterns in blood for the early detection of
cancer. At Predicant, David was Vice President of Development and Operations, responsible for managing Predicant’s product and commercial development efforts. Prior to
Predicant, David has held senior management positions with several companies focused on bringing novel products successfully into the marketplace, including as Vice
President of Product Development at EXACT Sciences, CEO of Union Biometrica, prior to that company’s acquisition by Harvard Biosciences, and Vice
President at BD Biosciences, a division of Becton, Dickinson and Company. David is also a co-founder of Cephos Corporation, an early stage company focused on the
use of functional magnetic resonance imaging for deception detection.
David Deems joined Xceed Molecular from Predicant Biosciences, an early stage proteomics company working to identify protein patterns in blood for the early detection of
cancer. At Predicant, David was Vice President of Development and Operations, responsible for managing Predicant’s product and commercial development efforts. Prior to
Predicant, David has held senior management positions with several companies focused on bringing novel products successfully into the marketplace, including as Vice
President of Product Development at EXACT Sciences, CEO of Union Biometrica, prior to that company’s acquisition by Harvard Biosciences, and Vice
President at BD Biosciences, a division of Becton, Dickinson and Company. David is also a co-founder of Cephos Corporation, an early stage company focused on the
use of functional magnetic resonance imaging for deception detection.
